Long Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Long Jin has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Haochen Wang
Capital Med Univ, Beijing Friendship Hosp, Dept Intervent Radiol, 59 Yongan Rd, Beijing 100050, Peoples R China
5 shared publicationsJian Li
Department of Radiological Intervention, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China
4 shared publicationsYanjing Han
Capital Med Univ, Beijing Friendship Hosp, Dept Intervent Radiol, 59 Yongan Rd, Beijing 100050, Peoples R China
4 shared publicationsGuang Chen
Department of Interventional Radiology, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China
3 shared publicationsShasha Cao
Capital Med Univ, Beijing Friendship Hosp, Dept Intervent Radiol, 59 Yongan Rd, Beijing 100050, Peoples R China
3 shared publicationsXuedong Sun
Department of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, PR China
3 shared publications
Latest Publications
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 2599-2609
Safety and Efficacy of TACE Combined with Lenvatinib and Pembrolizumab in Advanced Hepatocellular Carcinoma (BCLC C): A Retrospective Study
Background: There is relatively scant evidence concerning the effects of Lenvatinib and Pembrolizumab together with TACE for advanced HCC Lenvatinib and pembrolizumab have been widely applied in clinical settings. PIVKA-II serving as the sensitive biomarker for evaluating liver cancer was employed by us to further assess the therapeutic effectiveness of TACE combined with Lenvatinib in the treatment of BCLC C. Methods: In this retrospective study, 260 patients with HCC BCLC C stage were included in the present study. TACE (TL group) included 126 patients, TACE-Lenvatinib-Pembrolizumab (TPB group) consisted of 134 patients. OS and PFS were compared between the two groups. Alternatively, the impact of PIVKA-II in TPB on the PFS of BCLC C stage was also assessed. Results: The median overall survival (OS) in the TL group was significantly prolonged compared to that in the TPB group (13.7 months versus 9.6 months). Conversely, the median progression - free survival (PFS) was extended in the TPB group as opposed to the TL group (9.3 months versus 6.2 months). The adverse events in the TPB group were controllable and tolerable. After six months of combined treatment, the change in PIVKA - II became less significant. This suggests that PIVKA-II is negatively correlated with PFS, meaning that the greater the decrease in PIVKA-II after 6 months of combined therapy, the longer the PFS time for the patient. Conclusion: TACE combined with Lenvatinib and Pembrolizumab exhibited remarkable survival benefits for HCC BCLC C patients. Given the extremely dismal prognosis of advanced HCC, the safety and efficacy of TACE in combination with Lenvatinib and Pembrolizumab justify its clinical application.
- 1 November 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 2599-2609
Open AccessSafety and Efficacy of TACE Combined with Lenvatinib and Pembrolizumab in Advanced Hepatocellular Carcinoma (BCLC C): A Retrospective Study
Background: There is relatively scant evidence concerning the effects of Lenvatinib and Pembrolizumab together with TACE for advanced HCC Lenvatinib and pembrolizumab have been widely applied in clinical settings. PIVKA-II serving as the sensitive biomarker for evaluating liver cancer was employed by us to further assess the therapeutic effectiveness of TACE combined with Lenvatinib in the treatment of BCLC C. Methods: In this retrospective study, 260 patients with HCC BCLC C stage were included in the present study. TACE (TL group) included 126 patients, TACE-Lenvatinib-Pembrolizumab (TPB group) consisted of 134 patients. OS and PFS were compared between the two groups. Alternatively, the impact of PIVKA-II in TPB on the PFS of BCLC C stage was also assessed. Results: The median overall survival (OS) in the TL group was significantly prolonged compared to that in the TPB group (13.7 months versus 9.6 months). Conversely, the median progression - free survival (PFS) was extended in the TPB group as opposed to the TL group (9.3 months versus 6.2 months). The adverse events in the TPB group were controllable and tolerable. After six months of combined treatment, the change in PIVKA - II became less significant. This suggests that PIVKA-II is negatively correlated with PFS, meaning that the greater the decrease in PIVKA-II after 6 months of combined therapy, the longer the PFS time for the patient. Conclusion: TACE combined with Lenvatinib and Pembrolizumab exhibited remarkable survival benefits for HCC BCLC C patients. Given the extremely dismal prognosis of advanced HCC, the safety and efficacy of TACE in combination with Lenvatinib and Pembrolizumab justify its clinical application.
- Open Access
- 8 October 2024
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-9
CT-guided microcoil versus hook-wire localization of pulmonary nodule prior to video-assisted thoracoscopic surgery without fluoroscopic guidance
Both microcoils and hook-wires are commonly utilized for preoperative pulmonary nodule localization due to their convenience, but it remains unclear which one should be prioritized for recommendation. To compare the safety and efficacy of microcoils and hook-wires for pulmonary nodule localization. From January 2021 to December 2021, 310 consecutive patients (113 males and 197 females) with 341 pulmonary nodules who underwent CT-guided microcoil or hook-wire localization prior to video-assisted thoracoscopic surgery (VATS) at our center were retrospectively included in this study. There were 161 patients in the microcoil group and 149 patients in the hook-wire group. The successful localization rate, complication rate, radiation exposure, and medical costs were compared between the two groups. A total of 341 pulmonary nodules were localized, with a success rate of 99% (180/184) in the microcoil group and 93% (146/157) in the hook-wire group, respectively. All patients successfully underwent VATS. Multivariate analysis revealed that hook-wire localization, shorter needle depth into the lung tissue and the longer waiting time from localization to VATS were the risk factors for the localization failure. The incidences of pneumothorax in the microcoil group and hook-wire group were 34.8% (56/161) and 34.9% (52/149), respectively (P = 0.983). The incidences of pneumorrhagia were 13% (24/184) and 46.5% (73/157), respectively (P = 0.000). Multivariate analysis revealed that hook-wire localization and greater depth of needle penetration into lung tissue were risk factors for pneumorrhagia. Microcoil localization of pulmonary nodules is superior to hook-wire localization in terms of efficacy and safety. This finding provides insight into priority and broader promotion of microcoil localization.
- 8 October 2024
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-9
Open AccessCT-guided microcoil versus hook-wire localization of pulmonary nodule prior to video-assisted thoracoscopic surgery without fluoroscopic guidance
Both microcoils and hook-wires are commonly utilized for preoperative pulmonary nodule localization due to their convenience, but it remains unclear which one should be prioritized for recommendation. To compare the safety and efficacy of microcoils and hook-wires for pulmonary nodule localization. From January 2021 to December 2021, 310 consecutive patients (113 males and 197 females) with 341 pulmonary nodules who underwent CT-guided microcoil or hook-wire localization prior to video-assisted thoracoscopic surgery (VATS) at our center were retrospectively included in this study. There were 161 patients in the microcoil group and 149 patients in the hook-wire group. The successful localization rate, complication rate, radiation exposure, and medical costs were compared between the two groups. A total of 341 pulmonary nodules were localized, with a success rate of 99% (180/184) in the microcoil group and 93% (146/157) in the hook-wire group, respectively. All patients successfully underwent VATS. Multivariate analysis revealed that hook-wire localization, shorter needle depth into the lung tissue and the longer waiting time from localization to VATS were the risk factors for the localization failure. The incidences of pneumothorax in the microcoil group and hook-wire group were 34.8% (56/161) and 34.9% (52/149), respectively (P = 0.983). The incidences of pneumorrhagia were 13% (24/184) and 46.5% (73/157), respectively (P = 0.000). Multivariate analysis revealed that hook-wire localization and greater depth of needle penetration into lung tissue were risk factors for pneumorrhagia. Microcoil localization of pulmonary nodules is superior to hook-wire localization in terms of efficacy and safety. This finding provides insight into priority and broader promotion of microcoil localization.
- Open Access
- 5 October 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (2) , 101585
Development and external validation of a machine-learning based model to predict pre-sarcopenia in MASLD population: Results from NHANES 2017–2018
- 5 October 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (2) , 101585
Open AccessDevelopment and external validation of a machine-learning based model to predict pre-sarcopenia in MASLD population: Results from NHANES 2017–2018
- 26 September 2024
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 204, 104522
Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials
- 26 September 2024
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 204, 104522
Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials
- Open Access
- 2 April 2024
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 15 (2) , 710-720
Efficacy and safety analysis of selective hepatic vein occlusion combined with arterial chemoembolization versus conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma
Background: Transarterial chemoembolization (TACE) is a non-radical treatment. How to improve the local response rate of tumor is the direction we have been exploring. The purpose of this study is to compare the efficacy and safety of occlusion-TACE (O-TACE) versus conventional TACE (C-TACE) in the treatment of patients with early to mid-stage hepatocellular carcinoma (HCC) of lesions being confined to the same hepatic venous drainage area. Methods: In this study, 40 patients with HCC were prospectively enrolled and randomly assigned to the O-TACE and C-TACE groups, and the efficacy of all patients was assessed at 1, 2, and 3 months after the first treatment, and adverse events (AEs) occurring during the treatment period were also recorded. Results: At 1, 2 and 3 months after the first treatment, patients in the O-TACE group had significantly better complete response (CR) rates (35% vs. 5%, P=0.04; 50% vs. 15%, P=0.04; 70% vs. 30%, P=0.02) than those in the C-TACE group. The most common AE was abdominal pain, and the liver function indexes of patients in both groups returned to the baseline level at 1 month after the first treatment, and there was no statistically significant difference in the rate of AEs between the two groups. Conclusions: O-TACE has a better CR rate and a favorable safety profile in patients with early to mid-stage HCC of lesions being confined to the same hepatic venous drainage area.
- 2 April 2024
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 15 (2) , 710-720
Open AccessEfficacy and safety analysis of selective hepatic vein occlusion combined with arterial chemoembolization versus conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma
Background: Transarterial chemoembolization (TACE) is a non-radical treatment. How to improve the local response rate of tumor is the direction we have been exploring. The purpose of this study is to compare the efficacy and safety of occlusion-TACE (O-TACE) versus conventional TACE (C-TACE) in the treatment of patients with early to mid-stage hepatocellular carcinoma (HCC) of lesions being confined to the same hepatic venous drainage area. Methods: In this study, 40 patients with HCC were prospectively enrolled and randomly assigned to the O-TACE and C-TACE groups, and the efficacy of all patients was assessed at 1, 2, and 3 months after the first treatment, and adverse events (AEs) occurring during the treatment period were also recorded. Results: At 1, 2 and 3 months after the first treatment, patients in the O-TACE group had significantly better complete response (CR) rates (35% vs. 5%, P=0.04; 50% vs. 15%, P=0.04; 70% vs. 30%, P=0.02) than those in the C-TACE group. The most common AE was abdominal pain, and the liver function indexes of patients in both groups returned to the baseline level at 1 month after the first treatment, and there was no statistically significant difference in the rate of AEs between the two groups. Conclusions: O-TACE has a better CR rate and a favorable safety profile in patients with early to mid-stage HCC of lesions being confined to the same hepatic venous drainage area.
- Open Access
- 1 May 2023
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 29 (3) , 450-459
Comparison of quantitative volumetric analysis and linear measurement for predicting the survival of Barcelona Clinic Liver Cancer 0- and A stage hepatocellular carcinoma after radiofrequency ablation
PURPOSE The prognostic role of the tumor volume in patients with hepatocellular carcinoma (HCC) at the Barcelona Clinic Liver Cancer (BCLC) 0 and A stages remains unclear. This study aims to compare the volumetric measurement with linear measurement in early HCC burden profile and clarify the optimal cut-off value of the tumor volume.METHODS The consecutive patients diagnosed with HCC who underwent initial and curative-intent radiofre-quency ablation (RFA) were included retrospectively. The segmentation was performed semi -auto-matically, and enhanced tumor volume (ETV) as well as total tumor volume (TTV) were obtained. The patients were categorized into high-and low-tumor burden groups according to various cut-off values derived from commonly used diameter values, X-tile software, and decision-tree analysis. The inter-and intra-reviewer agreements were measured using the intra-class correlation coeffi-cient. Univariate and multivariate time-to-event Cox regression analyses were performed to identi-fy the prognostic factors of overall survival.RESULTS A total of 73 patients with 81 lesions were analyzed in the whole cohort with a median follow-up of 31.0 (interquartile range: 16.0-36.3). In tumor segmentation, excellent consistency was observed in intra-and inter-reviewer assessments. There was a strong correlation between diameter-derived spherical volume and ETV as well as ETV and TTV. As opposed to all linear candidates and 4,188 mm3 (sphere equivalent to 2 cm in diameter), ETV >14,137 mm3 (sphere equivalent to 3 cm in diameter) or 23,000 mm3 (sphere equivalent to 3.5 cm in diameter) was identified as an independent risk factor of survival. Considering the value of hazard ratio and convenience to use, when ETV was at 23,000 mm3, it was regarded as the optimal volumetric cut-off value in differentiating survival risk.CONCLUSION The volumetric measurement outperforms linear measurement on tumor burden evaluation for survival stratification in patients at BCLC 0 and A stages HCC after RFA.
- 1 May 2023
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 29 (3) , 450-459
Open AccessComparison of quantitative volumetric analysis and linear measurement for predicting the survival of Barcelona Clinic Liver Cancer 0- and A stage hepatocellular carcinoma after radiofrequency ablation
PURPOSE The prognostic role of the tumor volume in patients with hepatocellular carcinoma (HCC) at the Barcelona Clinic Liver Cancer (BCLC) 0 and A stages remains unclear. This study aims to compare the volumetric measurement with linear measurement in early HCC burden profile and clarify the optimal cut-off value of the tumor volume.METHODS The consecutive patients diagnosed with HCC who underwent initial and curative-intent radiofre-quency ablation (RFA) were included retrospectively. The segmentation was performed semi -auto-matically, and enhanced tumor volume (ETV) as well as total tumor volume (TTV) were obtained. The patients were categorized into high-and low-tumor burden groups according to various cut-off values derived from commonly used diameter values, X-tile software, and decision-tree analysis. The inter-and intra-reviewer agreements were measured using the intra-class correlation coeffi-cient. Univariate and multivariate time-to-event Cox regression analyses were performed to identi-fy the prognostic factors of overall survival.RESULTS A total of 73 patients with 81 lesions were analyzed in the whole cohort with a median follow-up of 31.0 (interquartile range: 16.0-36.3). In tumor segmentation, excellent consistency was observed in intra-and inter-reviewer assessments. There was a strong correlation between diameter-derived spherical volume and ETV as well as ETV and TTV. As opposed to all linear candidates and 4,188 mm3 (sphere equivalent to 2 cm in diameter), ETV >14,137 mm3 (sphere equivalent to 3 cm in diameter) or 23,000 mm3 (sphere equivalent to 3.5 cm in diameter) was identified as an independent risk factor of survival. Considering the value of hazard ratio and convenience to use, when ETV was at 23,000 mm3, it was regarded as the optimal volumetric cut-off value in differentiating survival risk.CONCLUSION The volumetric measurement outperforms linear measurement on tumor burden evaluation for survival stratification in patients at BCLC 0 and A stages HCC after RFA.
- Open Access
- 3 April 2023
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 13 (7) , 4077-4088
Imaging biomarkers on Angio-CT for predicting the efficacy of transarterial chemoembolization in hepatocellular carcinoma
Original Article Imaging biomarkers on Angio-CT for predicting the efficacy of transarterial chemoembolization in hepatocellular carcinoma Haochen Wang, Yanjing Han, Guang Chen, Long Jin
- 3 April 2023
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 13 (7) , 4077-4088
Open AccessImaging biomarkers on Angio-CT for predicting the efficacy of transarterial chemoembolization in hepatocellular carcinoma
Original Article Imaging biomarkers on Angio-CT for predicting the efficacy of transarterial chemoembolization in hepatocellular carcinoma Haochen Wang, Yanjing Han, Guang Chen, Long Jin
- Open Access
- 1 August 2022
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 13 (4) , 1907-1914
Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib
Original Article Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib Haochen Wang, Weizhong Xiao, Yanjing Han, Shasha Cao, Zhiyuan Zhang, Guang Chen, Yuefeng Hu, Long Jin
- 1 August 2022
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 13 (4) , 1907-1914
Open AccessStudy on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib
Original Article Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib Haochen Wang, Weizhong Xiao, Yanjing Han, Shasha Cao, Zhiyuan Zhang, Guang Chen, Yuefeng Hu, Long Jin
- Open Access
- 1 June 2022
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 13 (3) , 1248-1254
Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy
Original Article Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy Haochen Wang, Weizhong Xiao, Yanjing Han, Shasha Cao, Zhiyuan Zhang, Guang Chen, Yuefeng Hu, Long Jin
- 1 June 2022
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 13 (3) , 1248-1254
Open AccessStudy on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy
Original Article Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy Haochen Wang, Weizhong Xiao, Yanjing Han, Shasha Cao, Zhiyuan Zhang, Guang Chen, Yuefeng Hu, Long Jin
- Open Access
- 13 February 2020
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 41 (3) , 488-494
Large Neck and Strong Ostium Inflow as the Potential Causes for Delayed Occlusion of Unruptured Sidewall Intracranial Aneurysms Treated by Flow Diverter
BACKGROUND AND PURPOSE: Flow diverter–induced hemodynamic change plays an important role in the mechanism of intracranial aneurysm occlusion. Our aim was to explore the relationship between aneurysm features and flow-diverter treatment of unruptured sidewall intracranial aneurysms. MATERIALS AND METHODS: MR imaging, 4D phase-contrast, was prospectively performed before flow diverter implantation in each patient with unruptured intracranial aneurysm. Two postprocedure follow-ups were scheduled at 6 and 12 months. Responses were grouped according to whether the aneurysms were occluded or remnant. Preprocedural aneurysm geometries and ostium hemodynamics in 38 patients were compared between the 2 groups at 6 and 12 months. Receiver operating characteristic curve analyses were performed for significant geometric and hemodynamic continuous parameters. RESULTS: After the 6-month assessment, 21 of 41 intracranial aneurysms were occluded, and 9 additional aneurysms were occluded at 12 months. Geometrically, the ostium maximum diameter was significantly larger in the remnant group at 6 and 12 months (both P < .001). Hemodynamically, the proximal inflow zone was more frequently observed in the remnant group at 6 months. Several preprocedural ostium hemodynamic parameters were significantly higher in the remnant group. As a prediction for occlusion, the areas under the curve of the ostium maximum diameter (for 6 and 12 months), systolic inflow rate ratio (for 6 months), and systolic inflow area (for 12 months) reached 0.843, 0.883, 0.855, and 0.860, respectively. CONCLUSIONS: Intracranial aneurysms with a large ostium and strong ostium inflow may need a longer time for occlusion. Preprocedural 4D flow MR imaging can well illustrate ostium hemodynamics and characterize aneurysm treatment responses.
- 13 February 2020
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 41 (3) , 488-494
Open AccessLarge Neck and Strong Ostium Inflow as the Potential Causes for Delayed Occlusion of Unruptured Sidewall Intracranial Aneurysms Treated by Flow Diverter
BACKGROUND AND PURPOSE: Flow diverter–induced hemodynamic change plays an important role in the mechanism of intracranial aneurysm occlusion. Our aim was to explore the relationship between aneurysm features and flow-diverter treatment of unruptured sidewall intracranial aneurysms. MATERIALS AND METHODS: MR imaging, 4D phase-contrast, was prospectively performed before flow diverter implantation in each patient with unruptured intracranial aneurysm. Two postprocedure follow-ups were scheduled at 6 and 12 months. Responses were grouped according to whether the aneurysms were occluded or remnant. Preprocedural aneurysm geometries and ostium hemodynamics in 38 patients were compared between the 2 groups at 6 and 12 months. Receiver operating characteristic curve analyses were performed for significant geometric and hemodynamic continuous parameters. RESULTS: After the 6-month assessment, 21 of 41 intracranial aneurysms were occluded, and 9 additional aneurysms were occluded at 12 months. Geometrically, the ostium maximum diameter was significantly larger in the remnant group at 6 and 12 months (both P < .001). Hemodynamically, the proximal inflow zone was more frequently observed in the remnant group at 6 months. Several preprocedural ostium hemodynamic parameters were significantly higher in the remnant group. As a prediction for occlusion, the areas under the curve of the ostium maximum diameter (for 6 and 12 months), systolic inflow rate ratio (for 6 months), and systolic inflow area (for 12 months) reached 0.843, 0.883, 0.855, and 0.860, respectively. CONCLUSIONS: Intracranial aneurysms with a large ostium and strong ostium inflow may need a longer time for occlusion. Preprocedural 4D flow MR imaging can well illustrate ostium hemodynamics and characterize aneurysm treatment responses.